Liferna is a clinical and commercial stage biopharmaceutical company committed to delivering innovative treatment options for patients with oncological, autoimmune, fibrotic, neurological, and musculoskeletal diseases—globally, affordably, and at the speed patients deserve.
We operate through our Agile Pharma model, combining the speed and agility of biotechnology with the regulatory, operational, and commercialization capabilities of an integrated pharmaceutical organization. Our leadership team brings decades of experience developing, launching, and scaling medicines across global markets. We have built a company combining agility, operational excellence, and global reach to improve access to advanced care.
Liferna was founded on a fundamental conviction that novel medicines achieve their full potential when they reach the patients who need them most—through development, regulatory, and commercialization pathways designed to support broad access and long-term affordability.
We exist to close the gap between scientific innovation and real-world patient impact – by translating first-in-class and best-in-class assets into approved treatment options; by transforming approval into access across advanced and emerging markets; and by bringing life-changing medicines to more patients, in more places, with greater speed and affordability.
We believe the future of medicine will be defined not only by scientific progress, but by what patients are able to achieve because of it. Success means improving outcomes, reducing burden, and expanding what patients can expect from treatment.
Our ambition is to help shape a future where more patients can live healthier, fuller lives through access to novel treatment options across oncological, autoimmune, fibrotic, neurological, and musculoskeletal diseases.
We are pursuing that future with urgency, purpose, and a long-term commitment to patients.
We focus on identifying differentiated therapeutic programs with meaningful potential for patients and applying an agile, capital-efficient model to accelerate development and prepare for global commercialization and launch. Through purposeful execution, strategic collaboration, and scalable capabilities, we work to shorten the path from opportunity to patient impact and expand access to transformative treatment options worldwide.
Liferna’s leadership team possesses what is exceptionally rare in the biopharmaceutical industry: true end-to-end expertise spanning pre-clinical discovery, global clinical development, regulatory strategy, and full commercial launch, across multiple therapeutic modalities and international markets simultaneously. Collectively, the team has led and executed these efforts within some of the world’s largest pharmaceutical organizations, providing the operational, scientific, and strategic depth required to advance complex programs from concept through commercialization.
Liferna’s Scientific Advisory Board is composed of globally recognized key opinion leaders whose clinical, regulatory, and scientific expertise directly informs our development strategy across autoimmune, fibrotic, oncologic, and neurological disease areas. Our advisors are not passive consultants—they are active participants in shaping the programs that will define our pipeline.
LFR-1101 LFR-1101 is an investigational humanized anti-PD-1 monoclonal antibody being evaluated for treatment of multiple cancers, including cervical cancer.
Cervical cancer is a serious gynecologic malignancy often associated with persistent human papillomavirus (HPV) infection. While current treatment options can provide benefit, patients with advanced or recurrent disease continue to face significant unmet medical needs, highlighting the importance of developing new immunotherapy approaches designed to enhance anti-tumor immune responses.
LFR-1102 LFR-1102 is an investigational combination therapy consisting of LFR-1101 and a TROP2-directed antibody-drug conjugate (ADC) being evaluated for the treatment of non-small cell lung cancer (NSCLC).
Non-small cell lung cancer is the most common form of lung cancer and remains a leading cause of cancer-related mortality worldwide. Although advances in targeted therapies and immunotherapies have improved outcomes for some patients, many individuals with advanced or recurrent disease continue to experience disease progression. Additional treatment options may help address persistent challenges in disease management and improve outcomes for patients living with NSCLC.
LFR-1102 LFR-1102 is an investigational combination therapy consisting of LFR-1101 and a TROP2-directed antibody-drug conjugate (ADC) being evaluated for the treatment of triple-negative breast cancer (TNBC).
Triple-negative breast cancer is an aggressive form of breast cancer associated with a higher risk of recurrence and disease progression compared with many other breast cancer subtypes. Because these tumors do not express estrogen receptors, progesterone receptors, or HER2, treatment options may be limited for some patients with advanced disease. Despite advances in cancer therapy, significant unmet medical need remains, highlighting the importance of developing new treatment approaches designed to improve outcomes for patients with TNBC.
LFR-1103 LFR-1103 is an investigational combination therapy consisting of LFR-1101 and a FRα-directed antibody-drug conjugate (ADC) being evaluated for the treatment of platinum-resistant ovarian cancer (PROC).
Ovarian cancer is a serious gynecologic malignancy that is often diagnosed at an advanced stage. Although many patients initially respond to treatment, disease recurrence is common, and treatment options may become increasingly limited as the cancer develops resistance to platinum-based therapies. Platinum-resistant ovarian cancer remains a significant therapeutic challenge, highlighting the need for new treatment approaches designed to improve outcomes for patients with recurrent disease.
LFR-1103 LFR-1103 is an investigational combination therapy consisting of LFR-1101 and a FRα-directed antibody-drug conjugate (ADC) being evaluated for the treatment of endometrial cancer (EC).
Endometrial cancer is the most common gynecologic cancer in developed countries. While many patients are diagnosed at an early stage, those with advanced, recurrent, or metastatic disease may face a more challenging treatment journey. Despite recent advances in treatment, additional therapeutic options are needed for patients whose disease progresses following standard therapies, highlighting the importance of continued innovation in endometrial cancer care.
LFR-1201 LFR-1201 is an investigational small molecule therapy being developed through the U.S. FDA’s 505(b)(2) regulatory pathway for the treatment of idiopathic pulmonary fibrosis (IPF).
Idiopathic pulmonary fibrosis is a chronic, progressive lung disease characterized by the formation of scar tissue within the lungs. As the disease advances, lung function declines, making it increasingly difficult for patients to breathe and perform everyday activities. IPF is associated with substantial morbidity and mortality, and despite available treatments, many patients continue to experience disease progression. Additional therapeutic options are needed to help address the underlying fibrotic process and improve outcomes for individuals living with IPF.
LFR-1201 LFR-1201 is an investigational small molecule therapy being developed through the U.S. FDA’s 505(b)(2) regulatory pathway for patients with systemic sclerosis (SSc).
Systemic sclerosis is a rare chronic autoimmune disease characterized by progressive fibrosis of the skin and internal organs, as well as abnormalities of the blood vessels and immune system. Patients may experience skin thickening, pain, fatigue, reduced mobility, and potentially serious organ involvement that can significantly impact quality of life. Despite available treatment approaches that help manage symptoms and complications, there remains a need for additional therapies that address the underlying disease process and improve outcomes for individuals living with systemic sclerosis.
LFR-1501
Charcot-Marie-Tooth Disease Type 1 (CMT-1)
LFR-1501 LFR-1501 is an investigational neural regenerative progenitor cell (NRPC) therapy being evaluated for the treatment of Charcot-Marie-Tooth Disease Type 1 (CMT-1).
Charcot-Marie-Tooth Disease Type 1 is a rare inherited neurological disorder that affects the peripheral nerves responsible for muscle movement and sensation. The disease typically causes progressive muscle weakness, sensory loss, balance difficulties, and impaired mobility, which can significantly impact daily activities and quality of life. While supportive therapies may help manage symptoms, there are currently limited treatment options that address the underlying disease process. New therapeutic approaches are needed to help preserve nerve function and improve outcomes for individuals living with CMT-1.
LFR-1501
Diabetic Neuropathy (DN)
LFR-1501 LFR-1501 is an investigational neural regenerative progenitor cell (NRPC) therapy being evaluated for the treatment of diabetic neuropathy (DN).
Diabetic neuropathy is one of the most common complications of diabetes, resulting from progressive nerve damage associated with chronically elevated blood glucose levels. Patients may experience numbness, tingling, pain, weakness, and loss of sensation, particularly in the feet and lower extremities, which can significantly affect mobility, independence, and quality of life. While currently available treatments may help manage symptoms, additional therapeutic options are needed to address the underlying nerve damage and improve outcomes for individuals living with diabetic neuropathy.
LFR-1502
Osteoarthritis (OA)
LFR-1502 LFR-1502 is an investigational mesenchymal stem/stromal cell (MSSC) therapy being evaluated for the treatment of osteoarthritis (OA).
Osteoarthritis is the most common form of arthritis and a leading cause of pain, stiffness, and reduced mobility worldwide. The disease is characterized by the progressive degeneration of joint tissues, which can impair physical function and significantly impact quality of life. While currently available treatments may help manage symptoms, many patients continue to experience disease progression and functional decline. Additional therapeutic options are needed to help address the underlying disease process and improve outcomes for individuals living with osteoarthritis.
